A guide to appropriate
switching from VKAs
to Xarelto®
NVAF, Stroke prevention in adults with non-valvular atrial fibrillation and one or more risk factors, such as congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack.1
PP-XAR-GB-1231
© Bayer PLC, April 2020
Adverse event reporting and Xarelto® (rivaroxaban)
prescribing information can be accessed via the PI button.